<DOC>
	<DOCNO>NCT01768286</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy ledipasvir/sofosbuvir fix dose combination ( FDC ) without ribavirin ( RBV ) administer 12 24 week treatment-experienced subject chronic genotype 1 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir Fixed-Dose Combination Â± Ribavirin Treatment-Experienced Subjects With Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Age &gt; 18 , chronic genotype 1 HCV infection HCV treatmentexperienced , include patient previously fail nonstructural protein ( NS ) 3/4A protease inhibitor plus pegylated interferon ( PEG ) /RBV regimen HCV RNA &gt; 10,000 IU/mL screen Cirrhosis determination ; liver biopsy may require Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Coinfection HIV hepatitis B virus Current prior history clinical hepatic decompensation Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>HCV genotype 1 ( GT-1 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
</DOC>